Merck & Co., Inc. (1MRKX)
Summary
1MRKX Chart
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Don't Let Today's Bargain Opportunity Pass You By
Merck: Cheap Stock, But Still Relying Heavily On Keytruda (Rating Upgrade)
Merck & Co., Inc.'s heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Valuation has become attractive after a significant share price pullback, now trading at just 10x adjusted earnings and offering a 4% dividend yield. Despite expensive M&A and some new product launches, non-Keytruda sales remain flat, highlighting the urgent need for diversification.
40% Upside For Merck Stock?
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically positioning itself for further growth by diversifying and expanding its pipeline. Earlier this month, we highlighted how Keytruda is a ticking time bomb for Merck stock.
Merck & Co., Inc. Dividends
| MRK 3 months ago Paid | Quarterly | $0.81 Per Share |
| MRK 6 months ago Paid | Quarterly | $0.81 Per Share |
| MRK 9 months ago Paid | Quarterly | $0.77 Per Share |
| MRK 17 Jun 2024 Paid | Quarterly | $0.77 Per Share |
| MRK 14 Mar 2024 Paid | Quarterly | $0.77 Per Share |
Merck & Co., Inc. Earnings
| 29 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 1.67 Cons. EPS | 1.72 EPS |
| 31 Oct 2024 Date | | 1.5 Cons. EPS | 1.57 EPS |
| 30 Jul 2024 Date | | 2.15 Cons. EPS | 2.28 EPS |
| MRK 3 months ago Paid | Quarterly | $0.81 Per Share |
| MRK 6 months ago Paid | Quarterly | $0.81 Per Share |
| MRK 9 months ago Paid | Quarterly | $0.77 Per Share |
| MRK 17 Jun 2024 Paid | Quarterly | $0.77 Per Share |
| MRK 14 Mar 2024 Paid | Quarterly | $0.77 Per Share |
| 29 Jul 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
| 24 Apr 2025 Date | | - Cons. EPS | - EPS |
| 4 Feb 2025 Date | | 1.67 Cons. EPS | 1.72 EPS |
| 31 Oct 2024 Date | | 1.5 Cons. EPS | 1.57 EPS |
| 30 Jul 2024 Date | | 2.15 Cons. EPS | 2.28 EPS |
Merck & Co., Inc. (1MRKX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Merck & Co., Inc. ever had a stock split?
Merck & Co., Inc. Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Robert M. Davis CEO | XMIL Exchange | US58933Y1055 ISIN |
| US Country | 73,000 Employees | - Last Dividend | 3 Jun 2021 Last Split | 13 Jan 1978 IPO Date |
Overview
Merck & Co., Inc. is a global healthcare leader focused on innovating new solutions to tackle some of the most serious health challenges. Founded in 1891 and headquartered in Rahway, New Jersey, the company operates worldwide, engaging in the discovery, development, manufacturing, and marketing of pharmaceuticals and animal health products. It operates two main segments: Pharmaceutical and Animal Health. The Pharmaceutical segment is dedicated to developing and offering human health pharmaceutical products across a range of areas including oncology, cardiovascular, and diabetes, among others. The Animal Health segment works on veterinary pharmaceuticals, vaccines, and health management solutions and services. Merck serves a diverse clientele, including drug wholesalers, retailers, hospitals, government agencies, physicians, veterinarians, and pet owners. Notably, the company invests in several strategic collaborations and agreements with other pharmaceutical giants like AstraZeneca PLC and Bayer AG, aiming to enhance its product offerings and harness innovative treatments for multiple diseases.
Products and Services
The products and services offered by Merck & Co., Inc. span a broad spectrum of medical needs in both human and animal health sectors:
- Keytruda: A forefront immunotherapy for treating various types of cancer.
- Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia: A portfolio of pharmaceuticals addressing hospital acute care, neuroscience, virology, cardiovascular, and diabetes.
- Vaccine Products: Including preventive pediatric, adolescent, and adult vaccines with prominent products like Gardasil/Gardasil 9 for HPV, ProQuad, M-M-R II, and Varivax for measles, mumps, rubella, and chickenpox, RotaTeq for rotavirus, Vaxneuvance for pneumococcal infections, Pneumovax 23 for pneumonia, and Vaqta for hepatitis A.
- Animal Health Solutions: Veterinary pharmaceuticals, vaccines, health management solutions and services, along with digitally connected identification, traceability, and monitoring products aimed at veterinarians, distributors, animal producers, farmers, and pet owners.
In the arena of collaborative efforts, Merck has entered into multiple significant agreements to bolster its product pipeline:
- Daiichi Sankyo's deruxtecan ADC candidates: A development and commercialization agreement covering patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for treating multiple solid tumors.
- AstraZeneca's Lynparza and Koselugo: Co-development and co-commercialization for multiple cancer types, enhancing Merck's portfolio in oncology.
- Collaborations across the industry: Partnerships with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well as Moderna, Inc., aiming to explore and bring new treatments and vaccines to market.
Contact Information
